Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2016 May;72(5):513-21. doi: 10.1007/s00228-016-2011-7. Epub 2016 Jan 20.

Prevalence of statin-drug interactions in older people: a systematic review.

Author information

1
Faculty of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Sydney, NSW, 2006, Australia.
2
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
3
Kolling Institute of Medical Research, Royal North Shore Hospital, Level 12 Kolling Building, St Leonards, NSW, 2065, Australia.
4
Centre for Big Data Research in Health, UNSW Australia, Level 1, AGSM Building (G27), Sydney, NSW, 2052, Australia.
5
School of Public Health, The University of Sydney, Sydney, NSW, Australia.
6
Faculty of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au.
7
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. danijela.gnjidic@sydney.edu.au.

Abstract

PURPOSE:

Statins are among the most frequently prescribed medications internationally. Older people are commonly prescribed multiple medications and are at an increased risk of drug-drug interactions, including statin-drug interactions. The aim of this study was to conduct a systematic review of current evidence on the prevalence of statin-drug interactions in older people.

METHODS:

A systematic search of observational studies in Embase, Medline, and PubMed was conducted. Articles were included if they were published in English during the period July 2000-July 2014 and reported on the prevalence of statin-drug interactions in people over 65 years of age. Two reviewers independently assessed the articles for eligibility and extracted the data.

RESULTS:

The search returned 1556 eligible articles. A total of 19 articles met the inclusion criteria. In studies (n = 7) that focused on statin users only, the prevalence of potential statin-drug interactions assessed using different measures ranged from 0.19 to 33.0 %. In studies that examined drug interactions across a population of both statin users and non-users (n = 12), the prevalence of potential statin-drug interactions ranged from 0.1 to 7.1 % (n = 8), and the prevalence of clinically relevant statin-drug interactions ranged from 1.5 to 4 % (n = 4).

CONCLUSIONS:

Current published evidence suggests substantial variations in the prevalence of statin-drug interactions and their clinical relevance. Further studies are necessary to provide a better understanding of the prevalence of clinically significant statin-drug interactions, the medications most frequently contributing to statin-drug interactions, and impact on relevant clinical outcomes in older people.

KEYWORDS:

Drug-drug interactions; Older people; Prevalence; Statins

PMID:
26790666
DOI:
10.1007/s00228-016-2011-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center